Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
NCT01515813 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2016-02-01
Summary
Since people started taking HIV medications, illnesses related to AIDS have decreased, but other serious illnesses like heart disease (heart attacks) and certain kinds of cancer have increased. Studies show that HIV causes changes in the lining of the arteries and also causes inflammation (irritation) inside the body that may play a role in diseases like heart attacks and strokes. The levels of inflammation and artery lining health can also affect how well your brain works. These changes cannot be felt, but can be measured. Artery lining health can be looked at with a test that uses a blood pressure cuff on your arm to see how the artery responds when air is let in and out of the cuff. An ultrasound (machine that uses sound waves) is used to look at the artery during the test. This test is called Flow Mediated Dilation or FMD for short. Inflammation can be checked with blood tests (blood tests that measure this irritation inside the body that you cannot feel). HIV medications can improve the artery lining health and can partially lower levels of inflammation in the blood; however, these levels of inflammation may not be able to return back to normal.
Pravastatin sodium is a medication that is approved by the Food and Drug Administration (FDA) for treating high cholesterol. Pravastatin sodium has also been able to improve the health of the lining of the arteries and lower the level of inflammation in people with other diseases, but has not been studied or approved for this purpose in people who have HIV. This research study will look at the effects of two types of medications used separately or together on the health of the lining of arteries and levels of inflammation in the blood: Atripla (a HIV medication) and pravastatin sodium. This study will also look at the effects of Atripla and pravastatin sodium on cholesterol levels, tests that measure how well you can think and calculate (tests of neurocognitive function), and at the effects of Atripla on the levels of pravastatin sodium in the blood.
Conditions
- HIV-1 Infection
Interventions
- DRUG
-
Pravastatin sodium
One 40 mg tablet of Pravastatin sodium taken orally once daily.
- DRUG
-
Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
- DRUG
-
Pravastatin sodium
Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
lead NETWORK
Principal Investigators
-
David A. Wohl, M.D. · University of North Carolina AIDS CRS
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-30
- Primary Completion
- 2014-07-31
- Completion
- 2014-12-31
Countries
- United States
Study Locations
More Related Trials
-
Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients
NCT00128908 ·Status: TERMINATED ·Phase: PHASE4
-
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
NCT00781287 ·Status: TERMINATED ·Phase: PHASE4
-
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
NCT00775606 ·Status: TERMINATED ·Phase: PHASE4
-
The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)
NCT00076518 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus
NCT00102934 ·Status: UNKNOWN ·Phase: NA
-
Anti-HIV Medications for People Recently Infected With HIV
NCT00106171 ·Status: COMPLETED ·Phase: PHASE4
-
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
NCT00984152 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
NCT03631732 ·Status: COMPLETED ·Phase: PHASE3
-
Etiology of Treatment Failure in HIV Positive Children and Adolescents on Boosted Protease Inhibitor-based Regimens
NCT02689895 ·Status: COMPLETED ·Phase: NA
-
An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
NCT01541085 ·Status: COMPLETED
-
Early ART to Limit Infection and Establishment of Reservoir
NCT02859558 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparison of Two Anti-HIV Treatment Plans
NCT00005915 ·Status: COMPLETED
-
Effect of Raltegravir on Endothelial Function in HIV-Infected Patients
NCT00843713 ·Status: COMPLETED ·Phase: PHASE4
-
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
NCT05584397 ·Status: ENROLLING_BY_INVITATION
-
A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP
NCT00669487 ·Status: COMPLETED ·Phase: PHASE3
-
Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients
NCT00365612 ·Status: COMPLETED ·Phase: PHASE4
-
A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1
NCT00100984 ·Status: TERMINATED ·Phase: PHASE4
-
Effects of Intensive cART During Acute/Early HIV Infection
NCT01154673 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
NCT00738569 ·Status: COMPLETED ·Phase: NA
-
MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection
NCT00614458 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01475838 ·Status: COMPLETED ·Phase: PHASE3
-
Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption
NCT00355251 ·Status: TERMINATED ·Phase: PHASE4
-
CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
NCT00966160 ·Status: COMPLETED ·Phase: PHASE3
-
PREventing Progression of Adipose Tissue Redistribution
NCT00389194 ·Status: COMPLETED ·Phase: PHASE4
-
Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.
NCT00270556 ·Status: COMPLETED ·Phase: PHASE2